S&P 500 7,323.63 −0.23%
Nasdaq 24,429.89 +0.42%
S&P/TSX 34,578.05 −2.09%
Apple 352.45 +0.15%
Nvidia 150.96 −2.89%
Microsoft 508.29 +0.40%
Shopify 199.78 −1.50%
Royal Bank 272.26 −3.11%
CAD/USD 0.6993 −0.01%
PRE-MKT · 05:50 ET
Market ClerkRecap
Thu Nov 19 · pre-market7 signals on Nov 18520 insider buys this week · $248.1MCIRO short report next: Nov 30The week ahead

TSHA

Taysha Gene Therapies, Inc.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
3.99
−0.01 −0.25%
USD · close Nov 18

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

MKT CAP $1.3BP/E —DIV YIELD —FCF YIELD -10.20%REV TTM $5.5M −32.3%NET INCOME −$149.6MNET CASH $417.1M52W 3.51 – 6.98SEC XBRL · TTM TO Invalid Date

Financials

SEC XBRL · 33 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q2 2026 · Jun 30$0−100.0%—−$47.3M−$46.6M—-0.13−$40.4M−$1K−$40.4MAug 11
Q1 2026 · Mar 31$0−100.0%—−$43.5M−$42.4M—-0.12−$40.9M$24K−$40.9MMay 6
Q4 2025 · Dec 31derived$5.5M+171.3%—−$28.3M−$27.9M—-0.08−$26.7M$250K−$27MMar 19
Q3 2025 · Sep 30$0−100.0%—−$34M−$32.7M—-0.09−$24.2M$108K−$24.3MNov 4
Q2 2025 · Jun 30$2M+78.6%—−$26.8M−$26.9M—-0.09−$20.2M$2K−$20.2MAug 11
Q1 2025 · Mar 31$2.3M−32.5%—−$21.4M−$21.5M—-0.08−$22M$378K−$22.4MMay 6
Q4 2024 · Dec 31derived$2M−43.9%—−$19.9M−$18.8M−139.3%-0.07−$18.3M−$2K−$18.3MMar 19
Q3 2024 · Sep 30$1.8M−62.3%—−$25.9M−$25.5M—-0.10−$21.6M$35K−$21.6MNov 4
Q2 2024 · Jun 30$1.1M——−$21.3M−$20.9M—-0.09−$21.5M$201K−$21.7MAug 12
Q1 2024 · Mar 31$3.4M——−$24.3M−$24.1M—-0.10−$19.8M$140K−$19.9MMay 15
Q4 2023 · Dec 31derived$3.6M——−$16.2M$47.7M—0.92−$16.1M$17K−$16.1MFeb 26
Q3 2023 · Sep 30$4.7M——−$16.3M−$117.1M—-0.93−$17.9M$0−$17.9MNov 13

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2025 · to Dec 31$9.8M—−$110.5M−$109M-1115.3%-0.34−$93.1M$738K−$93.8M——
FY2024 · to Dec 31$8.3M—−$91.5M−$89.3M-1071.6%-0.36−$81.2M$374K−$81.6M——
FY2023 · to Dec 31$15.5M—−$72.4M−$111.6M-722.1%-0.96−$73M$3.9M−$76.9M——
FY2022 · to Dec 31$2.5M—−$162.4M−$166M-6635.3%-3.78−$88.4M$20.6M−$109M——
FY2021 · to Dec 31——−$173.3M−$174.5M—-4.64−$117M$15.3M−$132.3M——
FY2020 · to Dec 31——−$43M−$60M—-3.40−$30.7M$82K−$30.8M——

Every number comes from Taysha Gene Therapies, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch TSHA. Know when insiders buy.
One email the day a filing lands. Free.